Lixumistat With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
By Shubham Pant, MD - Last Updated: March 19, 2025At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Shubham Pant, MD, of The University of Texas MD Anderson Cancer Center, shared updates on a phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer.
Advertisement
Advertisement
Related Posts
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.